Literature DB >> 15315767

Lisinopril quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry.

Ana A F Padua1, Rafael E Barrientos-Astigarraga, Vinicius M Rezende, Gustavo D Mendes, Gilberto De Nucci.   

Abstract

An analytical method based on liquid chromatography with positive ion electrospray ionization (ESI) coupled to tandem mass spectrometry detection was developed for the determination of Lisinopril in human plasma using Enalaprilat as internal standard. The analyte and internal standard were extracted from the plasma samples by solid-phase extraction using Waters HLB Oasis SPE cartridges and chromatographed on a C8 analytical column. The mobile phase consisted of acetonitrile/water (60:40, v/v) + 20 mM acetic acid + 4.3 mM of triethylamine. The method had a chromatographic total run-time of 6.5 min and was linear within the range 2.00-200 ng/ml. Detection was carried out on a Micromass triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM). The precision (CV%) and accuracy, calculated from limit of quantification (LOQ) samples (n = 8), were 8.9 and 98.9%, respectively. The method herein described was employed in a bioequivalence study of two tablet formulations of Lisinopril 20mg. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315767     DOI: 10.1016/j.jchromb.2004.06.021

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Fast and sensitive LC-MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma.

Authors:  Jaivik V Shah; Priyanka A Shah; Priya V Shah; Mallika Sanyal; Pranav S Shrivastav
Journal:  J Pharm Anal       Date:  2016-11-25

2.  Switch on fluorescence probe for the selective determination of lisinopril in pharmaceutical formulations: application to content uniformity testing.

Authors:  Fatma F Mohammed; Khalid M Badr El-Din; Sayed M Derayea
Journal:  RSC Adv       Date:  2018-05-01       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.